finanzen.net
27.03.2020 02:05

Greenberg Traurig Assists Enlivex Therapeutics with $24.75 Million in Financing

Werbung

MIAMI, March 26, 2020 /PRNewswire-PRWeb/ -- Greenberg Traurig, P.A.Miami officeCorporate Shareholders Robert L. Grossman and Drew M. Altman represented Enlivex Therapeutics (Nasdaq: ENLV), a clinical-stage immunotherapy company, in two registered direct offerings aggregating $24.75 in financing for the company. The Tel Aviv, Israel-based company intends to use the net proceeds from the offerings for clinical, regulatory, manufacturing, and research and development activities, potential acquisitions, and in-licensing, as well as for working capital and other general corporate purposes.

On Feb. 26, Enlivex closed a registered direct offering to certain institutional investors of 1,000,000 ordinary shares of the company at a purchase price of $8.00 per share for aggregate gross proceeds of $8.0 million.

On March 5, Enlivex closed a registered direct offering to certain accredited and healthcare-focused institutional investors of an aggregate of 2,093,750 ordinary shares of the company and warrants to purchase up to an aggregate of 2,093,750 ordinary shares at a combined purchase price of $8.00 per share and associated warrant, for aggregate gross proceeds of $16.75 million.

Both offerings closed after Enlivex announced on Feb. 24 that it was initiating a plan to increase its manufacturing capacity of AllocetraTM, following the first confirmed coronavirus (COVID-19) case in Israel, in preparation for potential requests for treatment of coronavirus (COVID-19) patients who are hospitalized with diagnosed organ dysfunctions or failures related to coronavirus.

AllocetraTM is Enlivex's experimental therapy being investigated for treatment of patients with organ failure associated with sepsis, a syndrome whose lethal pathophysiology - cytokine storm followed by organ failure - is similar to that of the coronavirus (COVID-19).

"We were very pleased to assist Enlivex with these challenging offerings that were both completed within a much shorter than typical time frame," said Grossman, chair of the Greenberg Traurig Israel Practice, which includes the firm's Tel Aviv office. "We are the only major international law firm with a multidisciplinary registered office in Tel Aviv. Greenberg Traurig is well-positioned to provide assistance to Israel-based companies, many of which are in the life sciences industry."

"It was rewarding to complete these significant capital raising transactions for Enlivex," said Altman, who is chair of the firm's Miami Corporate Practice and counsels both public and private companies in securities matters, capital markets transactions, mergers and acquisitions, financing transactions and general corporate and business law matters. "Greenberg Traurig's ability to scale up quickly to meet client needs plays a key role in our ability to complete transactions of this type – wherever and whenever needed."

About Greenberg Traurig, LLP: Greenberg Traurig, LLP (GT) has approximately 2200 attorneys in 41 locations in the United States, Latin America, Europe, Asia, and the Middle East. GT has been recognized for its philanthropic giving, diversity, and innovation, and is consistently among the largest firms in the U.S. on the Law360 400 and among the Top 20 on the Am Law Global 100. Web: http://www.gtlaw.com Twitter: @GT_Law.

 

SOURCE Greenberg Traurig, P.A.

Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

Corona-Hoffnung: US-Börsen im Rallymodus -- DAX schließt über 10.000er-Marke -- Saudis steigen bei Carnival ein -- BMW-Absatz sinkt stark -- METRO, Delta, Boeing, LANXESS, HELLA, Allianz im Fokus

Apple liefert Gesichtsschutz für medizinisches Personal. JPMorgan sieht Dividenden trotz Corona-Krise gesichert. Commerzbank sieht sich durch Corona-Krise nicht in Gefahr. Varta-Aktie zieht an: Berenberg sieht zwei Drittel Erholungspotenzial. Fielmann trifft Vorbereitungen für Notbetrieb der Filialen. HUGO BOSS will in Corona-Krise auf Dividende verzichten.

Die 5 beliebtesten Top-Rankings

Rohstoffe: Die Gewinner und Verlierer im März 2020
Welcher Rohstoff macht das Rennen?
DAX 30: Die Gewinner und Verlierer im März 2020
Welche Aktie macht das Rennen?
TecDAX: Die Gewinner und Verlierer in Q1 2020
Welche Aktie macht das Rennen?
Die erfolgreichsten Kinofilme der letzten 25 Jahre
Welche Titel knackten die Milliardenmarke an den Kinokassen?
DAX: Die größten Verluste an nur einem Tag
An diesem Tagen verbuchte der DAX das höchste Minus
mehr Top Rankings

Umfrage

Corona-Crash an den Börsen: Wird der DAX im April noch weiter fallen?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Microsoft Corp.870747
Deutsche Bank AG514000
Wirecard AG747206
Scout24 AGA12DM8
Lufthansa AG823212
Daimler AG710000
Shell (Royal Dutch Shell) (A)A0D94M
TeslaA1CX3T
Airbus SE (ex EADS)938914
Amazon906866
Allianz840400
NEL ASAA0B733
Apple Inc.865985
BASFBASF11
BayerBAY001